Delving into the Latest Updates on Shuanghuanglian Oral Liquid with Synapse

Overview

Basic Info

Drug Type

Herbal medicine

Synonyms-

Target-

Mechanism-

Therapeutic Areas

Infectious DiseasesRespiratory Diseases

Active Indication

Common Cold

Inactive Indication-

Originator Organization

Heilongjiang Linbao Pharmaceutical Co., Ltd

Active Organization

Heilongjiang Linbao Pharmaceutical Co., Ltd

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

CN (14 Apr 2020),

Common Cold

Regulation-

Login to view timeline

In December 2019, an outbreak of novel coronavirus (2019-nCoV) occurred in Wuhan, Hubei Province, China. By February 14, 2020, it has led to 66 492 confirmed patients in China and high mortality up to ~2.96% (1123/37 914) in Wuhan. Here we report the first family case of coronavirus disease 2019 (COVID-19) confirmed in Wuhan and treated using the combination of western medicine and Chinese traditional patent medicine Shuanghuanglian oral liquid (SHL). This report describes the identification, diagnosis, clinical course, and management of three cases from a family, suggests the expected therapeutic effects of SHL on COVID-19, and warrants further clinical trials.

100 Deals associated with Shuanghuanglian Oral Liquid

Login to view more data